Lexicon Pharmaceuticals Prices $94.6M Public and Private Offerings
Analysis based on 11 articles · First reported Jan 29, 2026 · Last updated Jan 30, 2026
The market generally views this capital raise positively for Lexicon Pharmaceuticals, as it provides significant funding for R&D and operations. While the offering price was at a discount, the overall sentiment is that the company is strengthening its financial position for future growth.
Lexicon Pharmaceuticals announced the pricing of an underwritten public offering of 32 million shares of common stock at $1.30 per share, expected to generate $41.6 million. Concurrently, Lexicon Pharmaceuticals will sell 22.4 million common shares and 184,366 shares of Series B Convertible Preferred Stock to an affiliate of Invus, its largest stockholder, in a private placement, raising approximately $41.1 million. An additional $11.9 million could be raised from Invus's option to purchase more preferred shares. The total gross proceeds from both offerings are expected to be around $94.6 million. The funds will be used for research and development of drug candidates and general corporate purposes. Jefferies Financial Group and Piper Sandler Companies are joint book-running managers, with H.C. Wainwright & Co. as lead manager.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard